融捷健康(300247) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥99,373,210.78, a decrease of 16.53% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥21,457,778.48, an increase of 193.38% year-on-year[3] - The basic earnings per share for Q3 2021 was ¥0.0267, reflecting a growth of 193.31% compared to the previous year[3] - The total operating revenue for Q3 2021 was CNY 367,789,975.05, an increase of 3.9% compared to CNY 355,924,742.33 in the same period last year[27] - The net profit for Q3 2021 was CNY 36,549,298.46, a significant recovery from a net loss of CNY 22,625,816.44 in the previous year[28] - The company reported a gross profit margin of approximately 2.0% for Q3 2021, compared to a negative margin in the same quarter last year[27] - Basic and diluted earnings per share for Q3 2021 were CNY 0.0376, recovering from a loss of CNY 0.0424 in the same quarter last year[29] - The comprehensive income for Q3 2021 totaled CNY 33,487,828.02, a turnaround from a loss of CNY 24,646,276.97 in the previous year[28] Assets and Liabilities - Total assets at the end of Q3 2021 reached ¥1,000,443,875.58, representing a 4.59% increase from the end of the previous year[3] - The total assets as of Q3 2021 were CNY 1,000,443,875.58, up from CNY 956,578,278.65 at the end of the previous year[25] - The total liabilities increased to CNY 135,647,611.22 from CNY 125,269,842.33, reflecting a rise of 3.0%[25] - The company’s equity attributable to shareholders was CNY 835,487,341.96, compared to CNY 808,295,859.49 in the previous year, showing a growth of 3.4%[25] Cash Flow - The company reported a net cash flow from operating activities of -¥5,873,002.92 for the year-to-date, a decline of 108.72%[3] - The net cash flow from operating activities was -5,873,002.92, a decrease from 67,365,421.97 in the previous period, indicating a significant decline in operational performance[32] - Cash inflow from operating activities totaled 432,121,324.40, compared to 391,394,841.13 in the previous period, reflecting a year-over-year increase of approximately 10.4%[32] - Cash outflow from operating activities was 437,994,327.32, up from 324,029,419.16, representing a 35.3% increase[32] - Cash flow from investment activities showed a net outflow of -67,490,037.99, contrasting with a net inflow of 46,409,164.76 in the previous period[32] - The company reported cash and cash equivalents at the end of the period amounting to 85,996,726.11, down from 165,266,221.55, a decline of approximately 48%[32] Investments - Investment income for the year-to-date increased by 122.30%, amounting to an increase of ¥48,729,500 compared to the previous year[10] - The company completed the transfer of a 21% stake in Beijing Central Broadcasting United Media Investment Co., Ltd. for 70 million RMB[19] - The company has also transferred a 6.8232% stake in Anhui Yinglian Yunxiang Medical Technology Co., Ltd. for approximately 13.13 million RMB[20] - The company made a third investment payment of 27.5 million RMB to Zhongsheng Traceability Biotechnology Co., Ltd., completing its total investment commitment[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 39,659[14] - The largest shareholder, Rongjie Investment Holding Group Co., Ltd., holds 14.54% of shares, amounting to 116,912,302 shares, with 91,270,000 shares pledged[14] Operational Challenges - The company experienced a significant increase in cash outflow related to operating activities, which may impact future liquidity and operational strategies[32] - The company is focusing on improving cash flow management in light of the recent declines in both operating and investment cash flows[32] - The company has no preferred shareholders and no significant changes in restricted shares during the reporting period[16] Research and Development - Research and development expenses for Q3 2021 were CNY 9,969,905.85, an increase from CNY 8,725,943.55 in the previous year, indicating a focus on innovation[27] Audit and Compliance - The third-quarter report was not audited, which may affect the reliability of the financial data presented[34] - The company did not adjust the beginning balance of the balance sheet items due to the adoption of the new leasing standards, as it chose not to recognize right-of-use assets and lease liabilities[33]